In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide targeting β-catenin, a historically 'undruggable' protein, in just two months. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback